ATE340795T1 - Benzolsulfonsäureester-indol-5-yl als 5-ht6 rezeptor-antagonisten - Google Patents
Benzolsulfonsäureester-indol-5-yl als 5-ht6 rezeptor-antagonistenInfo
- Publication number
- ATE340795T1 ATE340795T1 AT02703087T AT02703087T ATE340795T1 AT E340795 T1 ATE340795 T1 AT E340795T1 AT 02703087 T AT02703087 T AT 02703087T AT 02703087 T AT02703087 T AT 02703087T AT E340795 T1 ATE340795 T1 AT E340795T1
- Authority
- AT
- Austria
- Prior art keywords
- acid ester
- receptor antagonist
- indol
- benzesulfonic
- benzesulfonic acid
- Prior art date
Links
- -1 ESTER INDOL-5-YL Chemical class 0.000 title 1
- 239000002253 acid Substances 0.000 title 1
- 239000003751 serotonin 6 antagonist Substances 0.000 title 1
- 108091005435 5-HT6 receptors Proteins 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Mechanical Treatment Of Semiconductor (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26499601P | 2001-01-30 | 2001-01-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE340795T1 true ATE340795T1 (de) | 2006-10-15 |
Family
ID=23008516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02703087T ATE340795T1 (de) | 2001-01-30 | 2002-01-17 | Benzolsulfonsäureester-indol-5-yl als 5-ht6 rezeptor-antagonisten |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US7230011B2 (de) |
| EP (1) | EP1377580B1 (de) |
| JP (1) | JP2004526699A (de) |
| CN (1) | CN1275967C (de) |
| AT (1) | ATE340795T1 (de) |
| AU (1) | AU2002236730B2 (de) |
| BR (1) | BR0206595A (de) |
| CA (1) | CA2433351A1 (de) |
| DE (1) | DE60214990T2 (de) |
| ES (1) | ES2272667T3 (de) |
| MX (1) | MXPA03006605A (de) |
| WO (1) | WO2002060871A2 (de) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2222830B1 (es) * | 2003-07-30 | 2006-02-16 | Laboratorios Del Dr. Esteve, S.A. | Derivados de 7-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos. |
| ES2222828B1 (es) * | 2003-07-30 | 2006-04-16 | Laboratorios Del Dr. Esteve, S.A. | Derivados de 1-sulfonilindoles, su preparacion y su aplicacion como medicamentos. |
| ES2222827B1 (es) * | 2003-07-30 | 2006-03-01 | Laboratorios Del Dr. Esteve, S.A. | Derivados de 5-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos. |
| ES2222832B1 (es) * | 2003-07-30 | 2006-02-16 | Laboratorios Del Dr. Esteve, S.A. | Derivados de 6-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos. |
| ES2222829B1 (es) | 2003-07-30 | 2006-03-01 | Laboratorios Del Dr. Esteve, S.A. | Derivados de 4-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos. |
| PL1704154T3 (pl) * | 2004-01-02 | 2009-10-30 | Suven Life Sciences Ltd | Nowe indeno[2,1a]indeny i izoindolo[2,1-a]indole |
| US20100105657A1 (en) * | 2005-07-05 | 2010-04-29 | Astrazeneca Ab | Compounds, Process for their Preparation, Intermediates, Pharmaceutical Compositions and their use in the Treatment of 5-HT6 Mediated Disorders such as Alzheimer's Disease, Cognitive Disorders, Cognitive Impairment Associated with Schizophrenia, Obesity and Parkinson's Disease |
| WO2007050381A2 (en) * | 2005-10-24 | 2007-05-03 | Janssen Pharmaceutica, N.V. | 3-piperidin-4-yl-indole orl-1 receptor modulators |
| WO2007098418A1 (en) | 2006-02-17 | 2007-08-30 | Memory Pharmaceuticals Corporation | Compounds having 5-ht6 receptor affinity |
| AR061637A1 (es) * | 2006-06-26 | 2008-09-10 | Epix Delaware Inc | Composiciones y metodos de tratamiento de trastornos del snc |
| CA2667547C (en) * | 2006-10-27 | 2014-07-29 | Boehringer Ingelheim International Gmbh | Piperidyl-propane-thiol ccr3 modulators |
| ATE524461T1 (de) * | 2006-10-27 | 2011-09-15 | Boehringer Ingelheim Int | Neue substituierte piperidylpropanthiole |
| MX2009006077A (es) | 2007-01-08 | 2009-06-17 | Suven Life Sciences Ltd | Compuestos de 5-(heterociclil)alquil-n-(arilsulfonil)indol y su uso como ligandos de la 5-hidroxitriptamina6. |
| KR101162482B1 (ko) | 2007-05-03 | 2012-07-03 | 수벤 라이프 사이언시스 리미티드 | 아미노알콕시 아릴술폰아미드 화합물 및 ５-ｈｔ６ 리간드로서의 그의 용도 |
| DK2200980T3 (da) | 2007-10-26 | 2011-11-21 | Suven Life Sciences Ltd | Aminoarylsulfonamidforbindelser og deres anvendelse som 5-HT6-ligander |
| US8318725B2 (en) | 2008-09-17 | 2012-11-27 | Suven Life Sciences Limited | Aryl indolyl sulfonamide compounds and their use as 5-HT6 ligands |
| HRP20130721T1 (en) | 2008-09-17 | 2013-09-30 | Suven Life Sciences Limited | Aryl sulfonamide amine compounds and their use as 5-ht6 ligands |
| US8563567B2 (en) | 2009-12-30 | 2013-10-22 | Arqule, Inc. | Substituted heterocyclic compounds |
| AU2010340745B2 (en) | 2010-01-05 | 2014-11-20 | Suven Life Sciences Limited | Sulfone compounds as 5-HT6 receptor ligands |
| KR101250606B1 (ko) * | 2011-01-24 | 2013-04-03 | 이화여자대학교 산학협력단 | 5-ｈｔ６ 수용체 억제 작용을 갖는 신규한 벤조티아졸 및 벤즈이소티아졸유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물 |
| AU2012321345B2 (en) * | 2011-10-03 | 2016-03-17 | The University Of Utah Research Foundation | Application of 5-HT6 receptor antagonists for the alleviation of cognitive deficits of down syndrome |
| WO2015082499A2 (en) * | 2013-12-03 | 2015-06-11 | Iomet Pharma Ltd | Pharmaceutical compound |
| EP3166924B1 (de) | 2014-07-08 | 2019-02-20 | Sunshine Lake Pharma Co., Ltd. | Aromatische heterocyclische derivate und pharmazeutische anwendungen davon |
| JP2018510131A (ja) * | 2015-01-30 | 2018-04-12 | ファイザー・インク | Ｒｏｒｃ２のスルホンアミド置換インドールモジュレーターおよびその使用方法 |
| WO2017023894A1 (en) * | 2015-08-03 | 2017-02-09 | Raze Therapeutics, Inc. | Mthfd2 inhibitors and uses thereof |
| CN115521307B (zh) * | 2022-09-30 | 2023-09-22 | 甘肃皓天医药科技有限责任公司 | 一种5-卤代-7-氮杂吲哚的制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69230803T2 (de) * | 1991-11-25 | 2000-12-07 | Pfizer Inc., New York | 5-(hetero- oder carbocyclylamino)-indol derivate, deren herstellung und deren verwendung als 5-ht1 agonisten |
| US5521196A (en) * | 1994-10-05 | 1996-05-28 | Eli Lilly And Company | 5-HT1F agonists for the treatment of migraine |
| US5521197A (en) * | 1994-12-01 | 1996-05-28 | Eli Lilly And Company | 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists |
| DE4444864A1 (de) * | 1994-12-16 | 1996-06-20 | Bayer Ag | Verwendung von 5-Acyl-1,4-dihydropyridinen |
| AU702322B2 (en) * | 1995-03-20 | 1999-02-18 | Eli Lilly And Company | 5-substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1h-indoles: new 5-ht1f agonists |
| AU7261196A (en) | 1995-10-10 | 1997-04-30 | Eli Lilly And Company | N-{2-substituted-3-(2-aminoethyl)-1h-indol-5-yl}-amides: new 5-ht1f agonists |
| WO1998015545A1 (en) * | 1996-10-08 | 1998-04-16 | Eli Lilly And Company | New serotonin 5-ht1f agonists |
| US6133287A (en) * | 1998-03-24 | 2000-10-17 | Allelix Biopharmaceuticals Inc. | Piperidine-indole compounds having 5-HT6 affinity |
| ES2291024T4 (es) | 1999-04-21 | 2009-03-01 | Nps Allelix Corp. | Compuestos de piperidina-indol con afinidad con 5-ht6. |
| WO2001009088A1 (en) | 1999-07-28 | 2001-02-08 | Kirin Beer Kabushiki Kaisha | Urea derivatives as inhibitors of ccr-3 receptor |
-
2002
- 2002-01-17 MX MXPA03006605A patent/MXPA03006605A/es active IP Right Grant
- 2002-01-17 US US10/466,969 patent/US7230011B2/en not_active Expired - Fee Related
- 2002-01-17 BR BR0206595-9A patent/BR0206595A/pt not_active IP Right Cessation
- 2002-01-17 CN CNB028043480A patent/CN1275967C/zh not_active Expired - Fee Related
- 2002-01-17 AT AT02703087T patent/ATE340795T1/de not_active IP Right Cessation
- 2002-01-17 JP JP2002561022A patent/JP2004526699A/ja active Pending
- 2002-01-17 WO PCT/US2002/000502 patent/WO2002060871A2/en not_active Ceased
- 2002-01-17 DE DE60214990T patent/DE60214990T2/de not_active Expired - Fee Related
- 2002-01-17 CA CA002433351A patent/CA2433351A1/en not_active Abandoned
- 2002-01-17 EP EP02703087A patent/EP1377580B1/de not_active Expired - Lifetime
- 2002-01-17 AU AU2002236730A patent/AU2002236730B2/en not_active Ceased
- 2002-01-17 ES ES02703087T patent/ES2272667T3/es not_active Expired - Lifetime
-
2007
- 2007-01-18 US US11/624,389 patent/US20070135484A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US7230011B2 (en) | 2007-06-12 |
| CN1489591A (zh) | 2004-04-14 |
| ES2272667T3 (es) | 2007-05-01 |
| WO2002060871A2 (en) | 2002-08-08 |
| WO2002060871A3 (en) | 2003-09-12 |
| MXPA03006605A (es) | 2003-09-22 |
| BR0206595A (pt) | 2004-07-13 |
| US20070135484A1 (en) | 2007-06-14 |
| DE60214990T2 (de) | 2007-04-05 |
| US20040102481A1 (en) | 2004-05-27 |
| AU2002236730B2 (en) | 2006-06-15 |
| EP1377580B1 (de) | 2006-09-27 |
| CA2433351A1 (en) | 2002-08-08 |
| CN1275967C (zh) | 2006-09-20 |
| EP1377580A2 (de) | 2004-01-07 |
| JP2004526699A (ja) | 2004-09-02 |
| WO2002060871A8 (en) | 2003-12-18 |
| DE60214990D1 (de) | 2006-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60214990D1 (de) | Benzolsulfonsäureester-indol-5-yl als 5-ht6 rezeptor-antagonisten | |
| ATE429427T1 (de) | Pyrimidinderivate als orexin-rezeptorantagonisten | |
| ATE372768T1 (de) | N-(2-arylethyl) benzylamine als 5-ht6 rezeptor- antagoniste | |
| PL211243B6 (pl) | Kompozycja farmaceutyczna antagonisty receptora tachykininy | |
| CY1112011T1 (el) | Παραγωγα αζαδικυκλο (3.1.0) εξανιου χρησιμα ως ρυθμιστες υποδοχεων d3 ντοπαμινης | |
| BRPI0414592A (pt) | antagonistas de receptores de trombina | |
| CY1108573T1 (el) | Ανταγωνιστες νρυυ5 | |
| CR20140316A (es) | Derivados de indol como antagonistas receptores de s1p1 (divisional 10922) | |
| ATE253545T1 (de) | Biarylessigsäure-derivate und ihre verwendung als cox-2 inhibitoren | |
| TR200201506T2 (tr) | Terapötik maddeler olarak kinaz inhibitörleri | |
| ATE384061T1 (de) | Imidazo- und thiazolopyridine als jak3-kinase- inhibitoren | |
| EA201101398A1 (ru) | Замещенные пиперидины в качестве антагонистов ccr3 | |
| ATE384039T1 (de) | Indanderivate als muscarinrezeptoragonisten | |
| WO2006021213A3 (en) | Vasopressin v1a antagonists | |
| MXPA05013474A (es) | Derivados de quinolilamida como antagonistas de ccr-5. | |
| EA200970341A1 (ru) | Пиразолиновые соединения в качестве антагонистов минералокортикоидных рецепторов | |
| ATE552246T1 (de) | Substituierte aryloxy-n- bicyclomethylacetamidverbindungen als vr1- antagonisten | |
| DE602005027230D1 (de) | Cgrp-rezeptorantagonisten | |
| EA200700365A1 (ru) | Производные индол-2-карбоксамидина как антагонисты nmda рецептора | |
| EA200400454A1 (ru) | Мускариновые агонисты | |
| MXPA05013149A (es) | Derivados de imidazol como antagonistas del receptor de glutamato. | |
| DE60041001D1 (de) | Substituierte homopiperidylbenzimidazolanaloga als fundusrelaxantien | |
| BR0307156A (pt) | Derivado de pirimidina bicìclica fundida, composto, antagonistas de receptores e agentes profiláticos e terapêuticos | |
| EA200700364A1 (ru) | Производные амида кинуреновой кислоты как антагонисты nr2b подтипа рецептора nmda | |
| EA200801549A1 (ru) | Новые производные фенантридина в качестве антагонистов брадикинина |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |